Similar articles

• Peginterferon alfa-2b plus ribavirin for chronic hepatitis.

  Picon PD, Costa AF, Kuchenbecker R, Beltrame A. Picon PD, et al. Lancet. 2002 Jan 19;359(9302):263; author reply 264. doi: 10.1016/S0140-6736(02)07429-9. Lancet. 2002. PMID: 11812597 No abstract available.
• Peginterferon alfa-2b plus ribavirin for chronic hepatitis.

  Cecil BD. Cecil BD. Lancet. 2002 Jan 19;359(9302):263-4. doi: 10.1016/S0140-6736(02)07430-5. Lancet. 2002. PMID: 11812598 No abstract available.
• Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.

  Buti M, Valdés A, Sánchez-Avila F, Esteban R, Lurie Y. Buti M, et al. Hepatology. 2003 May;37(5):1226-7. doi: 10.1053/jhep.2003.50107. Hepatology. 2003. PMID: 12717407 Clinical Trial. No abstract available.
• [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].

  Han KH, Yoon YH. Han KH, et al. Korean J Hepatol. 2004 Jun;10(2):81-7. Korean J Hepatol. 2004. PMID: 15218341 Review. Korean. No abstract available.
• Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.

  Ferenci P. Ferenci P. Int J Clin Pract. 2003 Sep;57(7):610-5. Int J Clin Pract. 2003. PMID: 14529063 Review.